

<b>Product Name</b>	: Encorafenib
<b>Synonyms</b>	: LGX818; LGX-818; LGX818; Encorafenib
<b>Cat No.</b>	: M17919
<b>CAS Number</b>	: 1269440-17-6
<b>Molecular Formula</b>	: C <sub>22</sub> H <sub>27</sub> ClFN <sub>7</sub> O <sub>4</sub> S
<b>Formula Weight</b>	: 540.01
<b>Chemical Name</b>	: (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate.
<b>Description</b>	Encorafenib, also known as LGX-818, is an orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells.
<b>Pathway</b>	: Cell Cycle/DNA Damage
<b>Target</b>	: HDAC
<b>Receptor</b>	: B-Raf (V600E)
<b>Solubility</b>	: DMSO : 50 mg/mL 92.59 mM;
<b>SMILES</b>	: <chem>C[C@@H](CNC1=NC=CC(=N1)C2=CN(N=C2C3=CC(=CC(=C3F)NS(=O)(=O)C)C(C)C)NC(=O)OC</chem>
<b>Storage</b>	: (-20°C)
<b>Stability</b>	: ≥ 2 years
<b>Reference</b>	:

1. Darrin D Stuart, et al. Cancer Res, 2012, 72(8 Supplement): 3790.